Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-16

Clinical Trial Update: Daratumumab in Treatment of PGNMID and C3 GN [Phase 2]

View source ↗

Summary

Phase 2 trial update for daratumumab in membranoproliferative glomerulonephritis showing completed status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Daratumumab (daratumumab)

Snippet

Sponsor: Fernando Fervenza | Conditions: Membranoproliferative Glomerulonephritis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-16